Clinical implications of CES2 RNA expression in neuroblastoma

Pindel, 1997, Purification and cloning of a broad substrate specificity human liver carboxylesterase that catalyzes the hydrolysis of cocaine and heroin, J Biol Chem, 272, 14769, 10.1074/jbc.272.23.14769 Humerickhouse, 2000, Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2, Cancer Res, 60, 1189 Senter, 2001, Identification and activities of human carboxylesterases for the activation of CPT-11, a clinically approved anticancer drug, Bioconjug Chem, 12, 1074, 10.1021/bc0155420 Zhang, 2002, Comprehensive evaluation of carboxylesterase-2 expression in normal human tissues using tissue array analysis, Appl Immunohistochem Mol Morphol, 10, 374, 10.1097/00129039-200212000-00015 Xu, 2002, Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan, Clin Cancer Res, 8, 2605 Dodds, 1998, Identification of a new metabolite of CPT-11 (irinotecan): pharmacological properties and activation to SN-38, J Pharmacol Exp Ther, 286, 578 Saltz, 1998, Irinotecan in the first-line treatment of colorectal cancer, Oncology (Williston Park), 12, 54 Saltz, 2001, Irinotecan: a new agent comes of age, Oncologist, 6, 65, 10.1634/theoncologist.6-1-65 Vanhoefer, 2001, Irinotecan in the treatment of colorectal cancer: clinical overview, J Clin Oncol, 19, 1501, 10.1200/JCO.2001.19.5.1501 Komuro, 1994, Effects of CPT-11 (a unique DNA topoisomerase I inhibitor) on a highly malignant xeno-transplanted neuroblastoma, Med Pediatr Oncol, 23, 487, 10.1002/mpo.2950230607 Vassal, 1996, Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts, Br J Cancer, 74, 537, 10.1038/bjc.1996.398 Blaney, 2001, A phase I study of irinotecan in pediatric patients: a pediatric oncology group study, Clin Cancer Res, 7, 32 Hirota, 2001, et al, Gan To Kagaku Ryoho, 28, 2049 Mugishima, 2002, Phase I study of irinotecan in pediatric patients with malignant solid tumors, J Pediatr Hematol Oncol, 24, 94, 10.1097/00043426-200202000-00007 Kushner, 2005, Five-day courses of irinotecan as palliative therapy for patients with neuroblastoma, Cancer, 103, 858, 10.1002/cncr.20846 Shitara, 2006, Irinotecan for children with relapsed solid tumors, Pediatr Hematol Oncol, 23, 103, 10.1080/08880010500457152 Satoh, 1994, Metabolic activation of CPT-11, 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin, a novel antitumor agent, by carboxylesterase, Biol Pharm Bull, 17, 662, 10.1248/bpb.17.662 Danks, 1999, Comparison of activation of CPT-11 by rabbit and human carboxylesterases for use in enzyme/prodrug therapy, Clin Cancer Res, 5, 917 Potter, 1998, In situ subcellular localization of epitope-tagged human and rabbit carboxylesterases, Cytometry, 32, 223, 10.1002/(SICI)1097-0320(19980701)32:3<223::AID-CYTO9>3.0.CO;2-K Guichard, 1999, CPT-11 converting carboxylesterase and topoisomerase activities in tumour and normal colon and liver tissues, Br J Cancer, 80, 364, 10.1038/sj.bjc.6690364 Khanna, 2000, Proficient metabolism of irinotecan by a human intestinal carboxylesterase, Cancer Res, 60, 4725 Wu, 2002, Irinotecan activation by human carboxylesterases in colorectal adenocarcinoma cells, Clin Cancer Res, 8, 2696 Ohtsuka, 2003, Intracellular conversion of irinotecan to its active form, SN-38, by native carboxylesterase in human non-small cell lung cancer, Lung Cancer, 41, 187, 10.1016/S0169-5002(03)00223-X Yano, 2008, Overexpression of carboxylesterase-2 results in enhanced efficacy of topoisomerase I inhibitor, irinotecan (CPT-11), for multiple myeloma, Cancer Sci, 99, 2309, 10.1111/j.1349-7006.2008.00936.x Inoue, 2006, Schedule-dependent cytotoxicity of 5-fluorouracil and irinotecan in a colon cancer cell line, J Gastroenterol, 41, 1149, 10.1007/s00535-006-1904-0 Tumilowicz, 1970, Definition of a continuous human cell line derived from neuroblastoma, Cancer Res, 30, 2110 Matsumura, 1987, Cell surface membrane antigen present on neuroblastoma cells but not fetal neuroblasts recognized by a monoclonal antibody (KP-NAC8), Cancer Res, 47, 2924 Mena, 1989, Biochemical properties of monoamine-rich human neuroblastoma cells, Brain Res, 486, 286, 10.1016/0006-8993(89)90514-3 Sugimoto, 1989, Differential susceptibility of HLA class II antigens induced by gamma-interferon in human neuroblastoma cell lines, Cancer Res, 49, 1824 Shikata, 1994, Increased expression of trk proto-oncogene by gamma-interferon in human neuroblastoma cell lines, Jpn J Cancer Res, 85, 122, 10.1111/j.1349-7006.1994.tb02070.x Kisenge, 2003, Expression of short-form caspase 8 correlates with decreased sensitivity to Fas-mediated apoptosis in neuroblastoma cells, Cancer Sci, 94, 598, 10.1111/j.1349-7006.2003.tb01489.x Kaneko, 1999, Treatment results of advanced neuroblastoma with the first Japanese study group protocol. Study Group of Japan for Treatment of Advanced Neuroblastoma, J Pediatr Hematol Oncol, 21, 190, 10.1097/00043426-199905000-00006 Tanaka, 2009, Clinical significance of the gene expression profile in residual tumor cells after neoadjuvant chemo-radiotherapy for esophageal cancer, Oncol Rep, 21, 1489, 10.3892/or_00000379 Bijwaard, 2001, Quantitative real-time reverse transcription-PCR assay for cyclin D1 expression: utility in the diagnosis of mantle cell lymphoma, Clin Chem, 47, 195, 10.1093/clinchem/47.2.195 Bland, 1998, Survival probabilities (the Kaplan–Meier method), BMJ, 317, 1572, 10.1136/bmj.317.7172.1572 Maris, 2010, Recent advances in neuroblastoma, N Engl J Med, 362, 2202, 10.1056/NEJMra0804577 Otake, 2011, HsMAD2 mRNA expression may be a predictor of sensitivity to paclitaxel and survival in neuroblastoma, Pediatr Surg Int, 27, 217, 10.1007/s00383-010-2780-5 Pavillard, 2002, Determinants of the cytotoxicity of irinotecan in two human colorectal tumor cell lines, Cancer Chemother Pharmacol, 49, 329, 10.1007/s00280-001-0416-0 Sanghani, 2003, Carboxylesterases expressed in human colon tumor tissue and their role in CPT-11 hydrolysis, Clin Cancer Res, 9, 4983 Marsh, 2004, Pharmacogenomic assessment of carboxylesterases 1 and 2, Genomics, 84, 661, 10.1016/j.ygeno.2004.07.008 Zitzelsberger, 1998, Genetic heterogeneity in a prostatic carcinoma and associated prostatic intraepithelial neoplasia as demonstrated by combined use of laser-microdissection, degenerate oligonucleotide primed PCR and comparative genomic hybridization, Virchows Arch, 433, 297, 10.1007/s004280050252 Rakha, 2004, Expression of E2F-4 in invasive breast carcinomas is associated with poor prognosis, J Pathol, 203, 754, 10.1002/path.1573 Zendman, 1999, TM7XN1, a novel human EGF-TM7-like cDNA, detected with mRNA differential display using human melanoma cell lines with different metastatic potential, FEBS Lett, 446, 292, 10.1016/S0014-5793(99)00230-6 Stranger, 2007, Relative impact of nucleotide and copy number variation on gene expression phenotypes, Science, 315, 848, 10.1126/science.1136678 Pawlik, 2000, Use of the ornithine decarboxylase promoter to achieve N-MYC-mediated overexpression of a rabbit carboxylesterase to sensitize neuroblastoma cells to CPT-11, Mol Ther, 1, 457, 10.1006/mthe.2000.0064 Danks, 2007, Tumor-targeted enzyme/prodrug therapy mediates long-term disease-free survival of mice bearing disseminated neuroblastoma, Cancer Res, 67, 22, 10.1158/0008-5472.CAN-06-3607 Vassal, 2003, A phase I study of irinotecan as a 3-week schedule in children with refractory or recurrent solid tumors, J Clin Oncol, 21, 3844, 10.1200/JCO.2003.08.175 Bomgaars, 2006, A phase I study of irinotecan administered on a weekly schedule in pediatric patients, Pediatr Blood Cancer, 46, 50, 10.1002/pbc.20355 Bomgaars, 2007, Phase II trial of irinotecan in children with refractory solid tumors: a Children's Oncology Group Study, J Clin Oncol, 25, 4622, 10.1200/JCO.2007.11.6103